about
Q202998-422873D2-CA47-49AB-921D-5E5DE11E0813Q27076889-99C277D4-A8B9-410D-BA3C-D7FBE3C61C5AQ27088425-0A266007-1DE0-46CA-B8A1-6769B86EF752Q27088744-34911E3C-8BA1-4F27-B5ED-F9279EB26AB5Q27089139-EC483707-68A2-4237-AAFF-F6A84E61D7DAQ27145209-7EE19529-0CD3-4A27-9C4B-9693F215C7C9Q27165308-C61036A1-91D2-435C-B1A5-43C84A636314Q27252567-C44DBC9B-23E3-427F-9D5D-AE0694701DF1Q417767-6A9E2E3D-ED9A-48C8-99FE-98942378BADDQ7238392-56CEDE11-E184-40B2-88BF-AA99C3949020Q928378-73C238A8-5E2C-4DA0-9B0E-1BAE0DC82EBE
P2868
description
A class of drugs designed to p ...... binding at the receptor level
@en
name
Leukotriene Antagonists
@en
مناهضات اللوكوترين
@ar
type
label
Leukotriene Antagonists
@en
مناهضات اللوكوترين
@ar
altLabel
Antagonists, Leukotriene
@en
Leukotriene Receptor Antagonists
@en
Receptor Antagonists, Leukotriene
@en
prefLabel
Leukotriene Antagonists
@en
مناهضات اللوكوترين
@ar
P486
P683
P486
P672
D27.505.696.399.450.565